IIR research report puts 31 cent target on Sienna


Last month, Independent Investment Research (IIR) initiated coverage on Sienna. The report recognises Sienna as the first company to develop an IVD product for the detection of hTERT.

IIR assigned Sienna a target price of $0.31, on a valuation range up to $0.81, based a number of assumptions regarding the sales of the IVD product over a ten-year period, with the high- end of the valuation range based on more aggressive market penetration assumptions. The valuation only assumes sales of the IVD product in the application of bladder cancer.


No Very

Captcha Image

Sign up for updates